American Journal of Kidney Diseases
Volume 46, Issue 5 , Pages 970-973 , November 2005

Hypothesis Versus Association: The Optimal Hemoglobin Target Debate

References 

  1. Levin A , Djurdjev O , Thompson C , et al.   Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD . Am J Kidney Dis . 2005;46:799–811
  2. Roger S , McMahon LP , Clarkson A , et al.   Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4) (Results of a randomized clinical trial) . J Am Soc Nephrol . 2004;15:148–156
  3. Parfrey PS , Foley RN , Wittreich BH , Sullivan DJ , Zagari MJ , Frei D . Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease . J Am Soc Nephrol . 2005;16:2180–2189
  4. Drüeke TB , Clyne N , Eckhardt KU , Locatelli F , MacDougall IC , Tsakaris D . Characteristics of chronic kidney disease patients enrolled in the Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin Beta (CREATE) study . J Am Soc Nephrol . 2002;13:520A; (abstr SUPO0257)
  5. Steinbrook R . Registration of clinical trials (Voluntary or mandatory?) . N Engl J Med . 2004;351:1820–1822
  6. Moher D , Schulz KF , Altman DG . The CONSORT statement (Revised recommendations for improving the quality of reports of parallel-group randomized trials) . Lancet . 2000;357:1191–1194
  7. Braunholtz DA , Edwards SJ , Lilford RJ . Are randomized clinical trials good for us (in the short term)? Evidence for a “trial effect” . J Clin Epidemiol . 2001;54:217–224
  8. Collins AJ , Ma JZ , Xia A , Ebben J . Trends in anemia treatment with erythropoietin usage and patient outcomes . Am J Kidney Dis . 1998;32(suppl 4):S133–S141
  9. Bucher HC , Guyatt GH , Cook DJ , et al.  Evidence-Based Working Group   Users’ guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate endpoints . JAMA . 1999;282:771–778
  10. Psaty BM , Weiss NS , Furberg CD , et al.   Surrogate endpoints, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease . JAMA . 1999;282:786–790
  11. Temple R . Are surrogate markers adequate to assess cardiovascular disease drugs? . JAMA . 1999;282:790–795
  12. Churchill DM , Thorpe KE , Vonesh EF , Keshaviah PR . Lower probability of patient survival with continuous peritoneal dialysis in the United States compared with Canada. Canada-USA (CANUSA) Peritoneal Dialysis Study Group . J Am Soc Nephrol . 1997;8:965–971
  13. Besarab A , Bolton WK , Browne JK , et al.   The effects of normal, as compared with low, hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin . N Engl J Med . 1998;339:584–590
  14. McMahon LP , Roger SD , Levin A  SLIMHEART Investigators Group . Development, prevention and potential reversal of left ventricular hypertrophy in chronic kidney disease . J Am Soc Nephrol . 2004;15:1640–1647
  15. Strippoli GF , Craig JC , Manno C , Schena FP . Hemoglobin targets for the anemia of chronic kidney disease (A meta-analysis of randomized, controlled trials) . J Am Soc Nephrol . 2004;15:3154–3165
  16. Leyland-Jones B  BEST Investigators and Study Group . Breast cancer trial with erythropoietin terminated unexpectedly . Lancet Oncol . 2003;4:459–460
  17. McDonald SP , Craig JC . Australian and New Zealand Paediatric Nephrology Association. Long-term survival of children with end-stage renal disease . N Engl J Med . 2004;350:2654–2662
  18. US Renal Data System. Available at: www.usrds.org Accessed: August 15, 2005.
  19. Australia and New Zealand Dialysis and Transplant Registry: Available at: www.anzdata.org.au. Accessed: August 15, 2005

PII: S0272-6386(05)01353-3

doi: 10.1053/j.ajkd.2005.09.009

American Journal of Kidney Diseases
Volume 46, Issue 5 , Pages 970-973 , November 2005

Article Tools